fampridine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4163 504-24-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fampyra
  • dalfampridine
  • ampyra
  • pyridin-4-amine
  • 4-aminopyridine
  • fampridine
One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes.
  • Molecular weight: 94.12
  • Formula: C5H6N2
  • CLOGP: 0.32
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 38.91
  • ALOGS: 0.46
  • ROTB: 0

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 90.30 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.04 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 2.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 112 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Jan. 22, 2010 FDA ACORDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 1963.23 14.64 831 38658 47647 63401886
Urinary tract infection 1451.44 14.64 1244 38245 263440 63186093
Laboratory test abnormal 1010.84 14.64 438 39051 26474 63423059
Balance disorder 767.03 14.64 537 38952 83885 63365648
Multiple sclerosis 730.90 14.64 339 39150 24033 63425500
Fall 706.66 14.64 1031 38458 391303 63058230
Gait disturbance 617.11 14.64 660 38829 182518 63267015
Urine analysis abnormal 598.43 14.64 191 39298 4825 63444708
Therapy cessation 502.05 14.64 283 39206 30174 63419359
Muscular weakness 408.10 14.64 439 39050 121914 63327619
Seizure 336.10 14.64 413 39076 132221 63317312
Muscle spasticity 241.38 14.64 157 39332 21637 63427896
Peroneal nerve palsy 225.82 14.64 92 39397 4743 63444790
Escherichia urinary tract infection 221.27 14.64 120 39369 11842 63437691
Insomnia 217.40 14.64 439 39050 214813 63234720
Lymphocyte count decreased 188.77 14.64 154 39335 30103 63419430
Central nervous system lesion 170.20 14.64 97 39392 10538 63438995
Gait inability 165.76 14.64 184 39305 52775 63396758
B-lymphocyte count decreased 161.27 14.64 49 39440 1045 63448488
Secondary progressive multiple sclerosis 160.59 14.64 52 39437 1375 63448158
Flushing 155.76 14.64 212 39277 74875 63374658
Dizziness 154.54 14.64 601 38888 429324 63020209
Memory impairment 148.60 14.64 247 39242 104011 63345522
Rheumatoid arthritis 139.47 14.64 4 39485 253815 63195718
Therapeutic response unexpected 137.48 14.64 105 39384 18654 63430879
Asthenia 136.73 14.64 535 38954 383069 63066464
Hypoaesthesia 134.95 14.64 313 39176 168080 63281453
Culture urine positive 131.70 14.64 58 39431 3629 63445904
Off label use 125.76 14.64 141 39348 674321 62775212
Micturition urgency 118.22 14.64 74 39415 9537 63439996
Paraesthesia 117.32 14.64 284 39205 156682 63292851
Systemic lupus erythematosus 115.84 14.64 3 39486 208915 63240618
Pollakiuria 114.19 14.64 112 39377 27825 63421708
Inappropriate schedule of product administration 111.90 14.64 218 39271 103747 63345786
Urine leukocyte esterase positive 110.97 14.64 51 39438 3528 63446005
Drug ineffective 110.68 14.64 1060 38429 1043705 62405828
Lymphopenia 109.52 14.64 91 39398 18236 63431297
Toxicity to various agents 106.48 14.64 14 39475 247236 63202297
Trigeminal neuralgia 105.53 14.64 49 39440 3470 63446063
Urinary incontinence 104.94 14.64 114 39375 31900 63417633
Product substitution issue 103.09 14.64 83 39406 15913 63433620
Dyspnoea 101.06 14.64 160 39329 661153 62788380
Head injury 97.65 14.64 102 39387 27294 63422239
Depression 96.57 14.64 305 39184 196187 63253346
JC polyomavirus test positive 93.90 14.64 35 39454 1418 63448115
Mobility decreased 91.33 14.64 220 39269 120939 63328594
Joint swelling 89.65 14.64 46 39443 327620 63121913
Glossodynia 87.88 14.64 6 39483 178870 63270663
Hand deformity 85.80 14.64 3 39486 159454 63290079
Neurogenic bladder 81.04 14.64 40 39449 3245 63446288
Anaemia 80.54 14.64 41 39448 293389 63156144
T-lymphocyte count increased 80.52 14.64 18 39471 104 63449429
Dysstasia 79.39 14.64 81 39408 21085 63428448
Bladder disorder 76.60 14.64 55 39434 8891 63440642
CD4 lymphocytes increased 75.89 14.64 18 39471 140 63449393
Infusion related reaction 75.73 14.64 29 39460 245492 63204041
Completed suicide 74.22 14.64 4 39485 145669 63303864
Exposure during pregnancy 74.17 14.64 6 39483 155541 63293992
T-lymphocyte count decreased 72.65 14.64 20 39469 296 63449237
Product use issue 71.49 14.64 24 39465 220496 63229037
Influenza like illness 70.49 14.64 139 39350 66685 63382848
Contraindicated product administered 70.01 14.64 24 39465 217624 63231909
Motor dysfunction 67.57 14.64 55 39434 10706 63438827
Progressive multiple sclerosis 67.54 14.64 26 39463 1152 63448381
Wound 66.20 14.64 11 39478 163252 63286281
Treatment failure 65.68 14.64 21 39468 199022 63250511
Arthralgia 65.24 14.64 163 39326 569547 62879986
Maternal exposure during pregnancy 64.59 14.64 28 39461 220034 63229499
Dysgraphia 64.04 14.64 34 39455 3212 63446321
Movement disorder 63.87 14.64 73 39416 21588 63427945
Walking aid user 63.58 14.64 53 39436 10664 63438869
CD4 lymphocytes decreased 62.71 14.64 26 39463 1401 63448132
Red blood cells urine positive 62.40 14.64 33 39456 3093 63446440
Acute kidney injury 60.87 14.64 45 39444 263370 63186163
Loss of control of legs 59.88 14.64 25 39464 1371 63448162
White blood cells urine positive 59.16 14.64 38 39451 5120 63444413
Arthropathy 58.39 14.64 37 39452 234755 63214778
Lower respiratory tract infection 58.11 14.64 7 39482 132300 63317233
Neutropenia 56.79 14.64 19 39470 174986 63274547
Muscle spasms 56.38 14.64 219 39270 155931 63293602
Gait spastic 56.28 14.64 16 39473 268 63449265
Feeling abnormal 55.94 14.64 211 39278 148181 63301352
Primary progressive multiple sclerosis 54.82 14.64 13 39476 101 63449432
CD8 lymphocytes decreased 54.68 14.64 14 39475 154 63449379
Sinusitis 54.62 14.64 37 39452 226616 63222917
Temperature intolerance 54.57 14.64 45 39444 8919 63440614
Product dose omission issue 53.48 14.64 287 39202 234026 63215507
Optic neuritis 52.72 14.64 43 39446 8392 63441141
Febrile neutropenia 52.68 14.64 6 39483 118443 63331090
Rash 52.13 14.64 177 39312 560694 62888839
Hemiparesis 50.15 14.64 67 39422 23215 63426318
Ataxia 49.59 14.64 54 39435 15141 63434392
Swelling 49.56 14.64 59 39430 275319 63174214
Drug intolerance 49.55 14.64 72 39417 308589 63140944
Epilepsy 49.51 14.64 72 39417 26993 63422540
Progressive multifocal leukoencephalopathy 49.30 14.64 50 39439 12921 63436612
Lymphocyte count abnormal 49.06 14.64 18 39471 697 63448836
Magnetic resonance imaging abnormal 48.98 14.64 28 39461 3057 63446476
Tremor 48.16 14.64 186 39303 132053 63317480
Burning sensation 47.80 14.64 105 39384 54302 63395231
Ankle fracture 47.36 14.64 57 39432 17798 63431735
Dysuria 46.76 14.64 79 39410 33659 63415874
Haemoglobin urine present 46.60 14.64 18 39471 805 63448728
Hypotension 46.34 14.64 61 39428 272543 63176990
Psoriatic arthropathy 45.13 14.64 3 39486 91517 63358016
Stomatitis 45.11 14.64 15 39474 138710 63310823
Urine abnormality 44.33 14.64 36 39453 6983 63442550
Diarrhoea 44.08 14.64 263 39226 715103 62734430
Blister 44.06 14.64 13 39476 129801 63319732
Product use in unapproved indication 43.45 14.64 29 39460 179051 63270482
Invasive ductal breast carcinoma 42.50 14.64 35 39454 6923 63442610
COVID-19 41.93 14.64 160 39329 112943 63336590
Escherichia test positive 41.55 14.64 23 39466 2361 63447172
Relapsing-remitting multiple sclerosis 41.03 14.64 15 39474 575 63448958
Extra dose administered 41.02 14.64 33 39456 6317 63443216
Status epilepticus 41.01 14.64 49 39440 15184 63434349
Musculoskeletal disorder 40.82 14.64 57 39432 20587 63428946
Pain 39.69 14.64 284 39205 740344 62709189
Nitrite urine present 38.82 14.64 17 39472 1049 63448484
Urine odour abnormal 38.74 14.64 32 39457 6357 63443176
Weight increased 36.98 14.64 66 39423 260726 63188807
Wheelchair user 36.96 14.64 31 39458 6288 63443245
Hip fracture 36.91 14.64 66 39423 29408 63420125
Blood immunoglobulin M decreased 36.77 14.64 16 39473 972 63448561
Cognitive disorder 36.41 14.64 96 39393 55719 63393814
Hypokinesia 36.16 14.64 44 39445 13892 63435641
Urinary tract infection pseudomonal 35.66 14.64 15 39474 838 63448695
General symptom 35.49 14.64 22 39467 2786 63446747
Generalised tonic-clonic seizure 35.09 14.64 64 39425 28952 63420581
Abdominal pain 35.04 14.64 82 39407 293374 63156159
Vitamin B12 increased 34.74 14.64 16 39473 1112 63448421
Drug hypersensitivity 34.61 14.64 90 39399 310597 63138936
Cystitis 34.27 14.64 93 39396 54898 63394635
Pancytopenia 34.21 14.64 9 39480 96924 63352609
Pleural effusion 34.16 14.64 8 39481 93202 63356331
Gastrointestinal haemorrhage 33.96 14.64 5 39484 81171 63368362
Urinary tract infection bacterial 33.90 14.64 27 39462 5095 63444438
Vomiting 33.75 14.64 207 39282 559410 62890123
Acute disseminated encephalomyelitis 33.42 14.64 10 39479 202 63449331
Drug interaction 33.37 14.64 57 39432 229074 63220459
Folliculitis 32.72 14.64 3 39486 70314 63379219
Therapy interrupted 32.40 14.64 66 39423 32389 63417144
Breast cancer 32.36 14.64 84 39405 48299 63401234
Sensory disturbance 32.01 14.64 41 39448 13631 63435902
Pneumonia 31.86 14.64 161 39328 456606 62992927
Lymphocyte percentage decreased 31.80 14.64 21 39468 2964 63446569
Limb discomfort 31.55 14.64 62 39427 29654 63419879
Adverse drug reaction 31.39 14.64 115 39374 79599 63369934
General physical health deterioration 30.35 14.64 49 39440 201353 63248180
Tongue biting 30.21 14.64 16 39473 1504 63448029
Muscle tightness 29.95 14.64 37 39452 11863 63437670
B-lymphocyte count abnormal 29.01 14.64 7 39482 59 63449474
Incontinence 29.01 14.64 36 39453 11596 63437937
Fatigue 28.94 14.64 739 38750 887289 62562244
Bacterial test positive 28.92 14.64 25 39464 5282 63444251
Glycosylated haemoglobin increased 28.75 14.64 37 39452 12361 63437172
Coordination abnormal 28.69 14.64 39 39450 13734 63435799
Decreased appetite 28.50 14.64 72 39417 250980 63198553
Respiratory failure 28.25 14.64 14 39475 101844 63347689
Hepatic enzyme increased 27.96 14.64 52 39437 202276 63247257
Platelet count decreased 27.89 14.64 19 39470 116103 63333430
Blood thyroid stimulating hormone decreased 27.85 14.64 23 39466 4567 63444966
Speech disorder 27.64 14.64 71 39418 40558 63408975
Thrombocytopenia 27.58 14.64 32 39457 151125 63298408
Fibromyalgia 27.38 14.64 8 39481 80412 63369121
Infection 27.37 14.64 64 39425 229109 63220424
Hypersensitivity 27.36 14.64 92 39397 292593 63156940
Impaired healing 27.10 14.64 15 39474 102527 63347006
Diplopia 27.02 14.64 51 39438 23677 63425856
Paraparesis 26.87 14.64 17 39472 2231 63447302
Asthma 26.68 14.64 24 39465 127537 63321996
Stress 26.53 14.64 97 39392 67070 63382463
Back pain 26.11 14.64 265 39224 263880 63185653
Urinary retention 26.06 14.64 58 39431 30243 63419290
Immune reconstitution inflammatory syndrome 25.99 14.64 25 39464 6059 63443474
Discomfort 25.90 14.64 40 39449 167334 63282199
Protein urine present 25.87 14.64 25 39464 6095 63443438
Decreased interest 25.58 14.64 19 39470 3235 63446298
Vitamin D deficiency 25.47 14.64 37 39452 13855 63435678
Invasive lobular breast carcinoma 25.41 14.64 12 39477 883 63448650
Urine ketone body present 25.20 14.64 17 39472 2486 63447047
Headache 24.86 14.64 541 38948 632700 62816833
Pyrexia 24.83 14.64 181 39308 470297 62979236
Urinary sediment present 24.70 14.64 16 39473 2187 63447346
Cardiac arrest 23.79 14.64 14 39475 92531 63357002
Intentional product use issue 23.41 14.64 27 39462 127865 63321668
Oxygen saturation decreased 23.35 14.64 13 39476 88572 63360961
Therapeutic product effect incomplete 23.33 14.64 26 39463 125030 63324503
Lymphocyte percentage abnormal 22.81 14.64 5 39484 26 63449507
Psoriasis 22.57 14.64 13 39476 86944 63362589
Intentional overdose 22.43 14.64 9 39480 74143 63375390
Hyponatraemia 22.29 14.64 22 39467 111878 63337655
Urge incontinence 22.23 14.64 11 39478 897 63448636
Irritable bowel syndrome 21.86 14.64 12 39477 82400 63367133
Urinary tract infection enterococcal 21.68 14.64 16 39473 2697 63446836
Peripheral swelling 21.32 14.64 89 39400 265853 63183680
Skin laceration 21.28 14.64 45 39444 22663 63426870
Hyperkalaemia 21.20 14.64 4 39485 54199 63395334
Wheezing 21.20 14.64 17 39472 95578 63353955
Cystitis klebsiella 20.68 14.64 7 39482 213 63449320
Dysarthria 20.65 14.64 66 39423 42645 63406888
Rectal haemorrhage 20.55 14.64 3 39486 49027 63400506
Urinary tract disorder 20.53 14.64 16 39473 2925 63446608
Human papilloma virus test positive 20.39 14.64 9 39480 566 63448967
Overdose 20.31 14.64 25 39464 115053 63334480
Initial insomnia 20.30 14.64 22 39467 6135 63443398
Hypoxia 20.26 14.64 6 39483 59786 63389747
Red blood cell count abnormal 20.20 14.64 11 39478 1093 63448440
Vertigo 19.20 14.64 81 39408 59806 63389727
International normalised ratio increased 19.09 14.64 3 39486 46422 63403111
Proteus test positive 19.06 14.64 7 39482 272 63449261
Inflammation 19.04 14.64 14 39475 82259 63367274
Visual impairment 18.92 14.64 103 39386 84343 63365190
Type 2 diabetes mellitus 18.92 14.64 8 39481 63860 63385673
Haematochezia 18.83 14.64 5 39484 53539 63395994
Anaphylactic reaction 18.45 14.64 9 39480 66091 63383442
Feeling hot 18.45 14.64 71 39418 50283 63399250
Depressed mood 18.43 14.64 61 39428 40130 63409403
Neutrophil percentage increased 18.39 14.64 15 39474 2928 63446605
Intraductal proliferative breast lesion 18.38 14.64 15 39474 2930 63446603
Metabolic acidosis 18.34 14.64 3 39486 45066 63404467
Contraindicated product prescribed 18.33 14.64 11 39478 1314 63448219
Prescribed underdose 18.28 14.64 50 39439 29639 63419894
Lymphocyte count increased 18.26 14.64 16 39473 3442 63446091
Therapeutic response changed 17.99 14.64 10 39479 1035 63448498
Hypertonic bladder 17.75 14.64 16 39473 3572 63445961
Living in residential institution 17.70 14.64 8 39481 532 63449001
Urosepsis 17.70 14.64 37 39452 18487 63431046
Arthritis 17.64 14.64 28 39461 115893 63333640
Blood pressure systolic increased 17.50 14.64 4 39485 47393 63402140
C-reactive protein increased 17.32 14.64 20 39469 94687 63354846
CD4 lymphocyte percentage decreased 17.07 14.64 3 39486 3 63449530
Urinary tract infection staphylococcal 17.06 14.64 7 39482 367 63449166
Hypoglycaemia 17.04 14.64 8 39481 60057 63389476
Vitamin D decreased 16.94 14.64 26 39463 10216 63439317
Bacterial test 16.90 14.64 10 39479 1164 63448369
Postictal paralysis 16.76 14.64 5 39484 100 63449433
Haematocrit abnormal 16.68 14.64 9 39480 878 63448655
Tachycardia 16.64 14.64 30 39459 118126 63331407
Focal dyscognitive seizures 16.41 14.64 14 39475 2907 63446626
Cardiac failure congestive 16.39 14.64 20 39469 92413 63357120
Bladder dysfunction 16.25 14.64 9 39480 925 63448608
Cardiac failure 16.11 14.64 19 39470 89123 63360410
Eye contusion 16.09 14.64 12 39477 2055 63447478
B-lymphocyte count increased 16.02 14.64 5 39484 117 63449416
Aphasia 15.96 14.64 51 39438 32949 63416584
Bone pain 15.94 14.64 7 39482 54634 63394899
Neutrophil count increased 15.78 14.64 33 39456 16494 63433039
Injection site scar 15.52 14.64 9 39480 1009 63448524
Citrobacter infection 15.48 14.64 7 39482 466 63449067
Pulmonary fibrosis 15.44 14.64 3 39486 39806 63409727
Multiple organ dysfunction syndrome 15.43 14.64 8 39481 56744 63392789
Glucose urine present 15.39 14.64 8 39481 724 63448809
Insurance issue 15.35 14.64 19 39470 6102 63443431
Postictal state 15.32 14.64 9 39480 1034 63448499
Lower limb fracture 15.12 14.64 41 39448 24180 63425353
Transferrin saturation decreased 14.99 14.64 8 39481 764 63448769
White blood cell count decreased 14.91 14.64 142 39347 138962 63310571
Impaired self-care 14.88 14.64 11 39478 1859 63447674
Intervertebral disc protrusion 14.67 14.64 40 39449 23669 63425864

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 1000.45 20.70 318 13452 12815 34930346
Multiple sclerosis 464.73 20.70 151 13619 6494 34936667
Balance disorder 332.41 20.70 204 13566 40450 34902711
Gait disturbance 307.90 20.70 260 13510 84880 34858281
Laboratory test abnormal 300.78 20.70 151 13619 20240 34922921
Urinary tract infection 296.30 20.70 253 13517 83828 34859333
Fall 287.84 20.70 375 13395 202510 34740651
Muscle spasticity 275.29 20.70 99 13671 5789 34937372
Drug ineffective 179.31 20.70 485 13285 456266 34486895
Relapsing-remitting multiple sclerosis 166.51 20.70 45 13725 1005 34942156
Muscular weakness 161.77 20.70 170 13600 72727 34870434
Central nervous system lesion 158.08 20.70 68 13702 6395 34936766
Gait spastic 155.35 20.70 43 13727 1053 34942108
Mobility decreased 147.15 20.70 110 13660 30018 34913143
Insomnia 137.28 20.70 186 13584 103721 34839440
Needle fatigue 136.16 20.70 37 13733 844 34942317
Movement disorder 127.60 20.70 72 13698 12176 34930985
Therapy cessation 122.96 20.70 79 13691 16894 34926267
Ataxia 116.79 20.70 71 13699 13782 34929379
Memory impairment 114.24 20.70 111 13659 43207 34899954
Hypertonic bladder 108.82 20.70 37 13733 1827 34941334
Micturition urgency 107.04 20.70 52 13718 6473 34936688
Monoparesis 100.50 20.70 37 13733 2309 34940852
Seizure 98.49 20.70 160 13610 104697 34838464
B-lymphocyte count decreased 94.69 20.70 26 13744 617 34942544
Secondary progressive multiple sclerosis 92.20 20.70 23 13747 370 34942791
Pollakiuria 89.75 20.70 69 13701 19605 34923556
Gait inability 84.35 20.70 68 13702 20690 34922471
Peroneal nerve palsy 77.98 20.70 33 13737 2978 34940183
Hypoaesthesia 75.00 20.70 106 13664 61338 34881823
Flushing 67.16 20.70 73 13697 32347 34910814
JC polyomavirus test positive 66.06 20.70 20 13750 677 34942484
Product substitution issue 63.41 20.70 43 13727 10052 34933109
Acute kidney injury 62.87 20.70 21 13749 304967 34638194
Trigeminal neuralgia 62.46 20.70 22 13748 1207 34941954
Therapeutic response unexpected 62.33 20.70 42 13728 9715 34933446
Anaemia 59.98 20.70 10 13760 233325 34709836
Dizziness 57.74 20.70 203 13567 218318 34724843
Progressive multifocal leukoencephalopathy 57.57 20.70 40 13730 9724 34933437
Nocturia 55.95 20.70 40 13730 10170 34932991
Influenza like illness 55.11 20.70 61 13709 27573 34915588
Hypotension 51.70 20.70 12 13758 221637 34721524
Dysarthria 51.56 20.70 66 13704 34716 34908445
Lymphocyte count decreased 48.70 20.70 52 13718 22570 34920591
Asthenia 48.57 20.70 208 13562 245043 34698118
Progressive multiple sclerosis 44.96 20.70 12 13758 255 34942906
Paraesthesia 44.71 20.70 86 13684 64086 34879075
Toxicity to various agents 44.49 20.70 12 13758 200350 34742811
Off label use 43.86 20.70 61 13709 419463 34523698
Dyspnoea 41.18 20.70 53 13717 376729 34566432
COVID-19 40.12 20.70 92 13678 77458 34865703
Neutropenia 39.63 20.70 7 13763 156771 34786390
Drug interaction 39.32 20.70 20 13750 225926 34717235
Erectile dysfunction 38.48 20.70 44 13726 20593 34922568
Urinary incontinence 38.20 20.70 42 13728 18832 34924329
Lymphocyte percentage decreased 38.02 20.70 18 13752 2114 34941047
Neurogenic bladder 37.61 20.70 17 13753 1796 34941365
Urine analysis abnormal 36.01 20.70 17 13753 1984 34941177
Muscle spasms 34.48 20.70 85 13685 74916 34868245
T-lymphocyte count decreased 33.17 20.70 9 13761 204 34942957
White blood cells urine positive 32.92 20.70 14 13756 1278 34941883
Decreased vibratory sense 31.79 20.70 10 13760 385 34942776
Cystitis 31.45 20.70 28 13742 9737 34933424
Paraparesis 30.81 20.70 15 13755 1874 34941287
Bladder disorder 30.60 20.70 18 13752 3286 34939875
Walking aid user 30.54 20.70 15 13755 1909 34941252
CD8 lymphocytes decreased 30.35 20.70 7 13763 79 34943082
Thrombocytopenia 30.02 20.70 12 13758 156235 34786926
Temperature intolerance 30.01 20.70 18 13752 3404 34939757
Cognitive disorder 29.91 20.70 46 13724 28647 34914514
Vitamin B12 increased 28.83 20.70 9 13761 338 34942823
Renal failure 28.61 20.70 8 13762 130549 34812612
Inappropriate schedule of product administration 27.99 20.70 70 13700 62226 34880935
Adverse drug reaction 26.42 20.70 44 13726 29298 34913863
Burning sensation 25.83 20.70 34 13736 18360 34924801
Fatigue 25.11 20.70 239 13531 370414 34572747
Diarrhoea 25.06 20.70 75 13695 389837 34553324
Musculoskeletal stiffness 24.80 20.70 56 13714 46624 34896537
Pancytopenia 24.57 20.70 4 13766 95153 34848008
Dysstasia 24.44 20.70 27 13743 12168 34930993
General symptom 23.93 20.70 10 13760 874 34942287
Herpes zoster 23.81 20.70 46 13724 34353 34908808
Platelet count decreased 23.31 20.70 9 13761 119708 34823453
Cardiac failure 23.20 20.70 4 13766 91244 34851917
Back pain 23.02 20.70 102 13668 121687 34821474
Motor dysfunction 22.46 20.70 20 13750 6954 34936207
Spinal cord injury cauda equina 21.48 20.70 6 13764 152 34943009
Depression 21.21 20.70 85 13685 97013 34846148
Somatosensory evoked potentials abnormal 21.01 20.70 6 13764 165 34942996
Generalised tonic-clonic seizure 20.75 20.70 33 13737 21141 34922020

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 2224.08 14.69 842 38428 45691 79659427
Urinary tract infection 1710.91 14.69 1263 38007 273249 79431869
Laboratory test abnormal 1616.92 14.69 583 38687 27465 79677653
Multiple sclerosis 737.87 14.69 310 38960 21972 79683146
Fall 710.62 14.69 1025 38245 486604 79218514
Balance disorder 674.14 14.69 482 38788 98375 79606743
Urine analysis abnormal 642.50 14.69 203 39067 6317 79698801
Gait disturbance 472.02 14.69 545 38725 206961 79498157
Muscular weakness 344.92 14.69 410 38860 160319 79544799
Muscle spasticity 343.98 14.69 181 39089 21294 79683824
Therapy cessation 343.74 14.69 220 39050 37342 79667776
B-lymphocyte count decreased 267.39 14.69 73 39197 1341 79703777
Seizure 266.13 14.69 392 38878 188442 79516676
Escherichia urinary tract infection 263.38 14.69 131 39139 13694 79691424
Central nervous system lesion 249.74 14.69 125 39145 13243 79691875
Peroneal nerve palsy 199.66 14.69 84 39186 5958 79699160
Gait spastic 195.10 14.69 55 39215 1142 79703976
Insomnia 193.70 14.69 394 38876 244776 79460342
Lymphocyte count decreased 187.53 14.69 168 39102 47121 79657997
Gait inability 181.51 14.69 182 39088 58735 79646383
Pollakiuria 181.43 14.69 149 39121 37168 79667950
Micturition urgency 181.22 14.69 99 39171 12542 79692576
Relapsing-remitting multiple sclerosis 177.87 14.69 54 39216 1465 79703653
Memory impairment 160.16 14.69 234 39036 111500 79593618
Secondary progressive multiple sclerosis 156.49 14.69 48 39222 1349 79703769
Culture urine positive 151.04 14.69 63 39207 4372 79700746
Movement disorder 149.88 14.69 117 39153 27142 79677976
Hypoaesthesia 141.24 14.69 288 38982 179064 79526054
Dizziness 134.04 14.69 563 38707 525878 79179240
Urine leukocyte esterase positive 132.25 14.69 56 39214 4035 79701083
Toxicity to various agents 130.10 14.69 25 39245 421515 79283603
Asthenia 123.11 14.69 538 38732 511151 79193967
Off label use 122.49 14.69 161 39109 907054 78798064
Therapeutic response unexpected 121.49 14.69 91 39179 19855 79685263
Needle fatigue 118.30 14.69 35 39235 867 79704251
Anaemia 116.76 14.69 37 39233 444978 79260140
Mobility decreased 115.47 14.69 212 39058 121963 79583155
Trigeminal neuralgia 115.33 14.69 49 39221 3560 79701558
Urinary incontinence 114.41 14.69 120 39150 40789 79664329
JC polyomavirus test positive 113.93 14.69 39 39231 1563 79703555
Acute kidney injury 107.83 14.69 61 39209 519343 79185775
Ataxia 107.32 14.69 93 39177 24946 79680172
T-lymphocyte count decreased 105.94 14.69 29 39241 538 79704580
T-lymphocyte count increased 102.40 14.69 21 39249 99 79705019
Progressive multifocal leukoencephalopathy 97.49 14.69 81 39189 20519 79684599
Flushing 97.42 14.69 164 39106 88104 79617014
Dyspnoea 96.46 14.69 172 39098 856853 78848265
Paraesthesia 96.29 14.69 245 39025 176078 79529040
Hypertonic bladder 95.68 14.69 45 39225 4156 79700962
White blood cells urine positive 93.83 14.69 50 39220 6025 79699093
Febrile neutropenia 93.28 14.69 5 39265 230994 79474124
COVID-19 92.31 14.69 225 39045 157449 79547669
Rheumatoid arthritis 89.19 14.69 3 39267 208467 79496651
Head injury 87.76 14.69 100 39170 37269 79667849
Monoparesis 87.40 14.69 40 39230 3471 79701647
CD8 lymphocytes decreased 85.52 14.69 21 39249 248 79704870
Lymphopenia 84.31 14.69 89 39181 30468 79674650
Neurogenic bladder 83.44 14.69 41 39229 4171 79700947
CD4 lymphocytes increased 83.39 14.69 21 39249 277 79704841
Product substitution issue 82.32 14.69 73 39197 20183 79684935
Neutropenia 80.78 14.69 21 39249 287689 79417429
Hypotension 78.78 14.69 61 39209 440256 79264862
Red blood cells urine positive 77.08 14.69 41 39229 4922 79700196
Completed suicide 76.98 14.69 14 39256 245753 79459365
Inappropriate schedule of product administration 72.21 14.69 185 39085 133443 79571675
Lymphocyte percentage decreased 68.64 14.69 38 39232 4938 79700180
Dysstasia 68.13 14.69 76 39194 27670 79677448
CD4 lymphocytes decreased 65.54 14.69 30 39240 2604 79702514
Influenza like illness 63.43 14.69 121 39149 71586 79633532
Drug interaction 61.84 14.69 68 39202 415115 79290003
Motor dysfunction 61.68 14.69 54 39216 14679 79690439
Bladder disorder 58.46 14.69 43 39227 9122 79695996
Dysuria 57.97 14.69 96 39174 50855 79654263
Vitamin B12 increased 57.94 14.69 22 39248 1191 79703927
Status epilepticus 57.08 14.69 66 39204 24975 79680143
Depression 56.60 14.69 234 39036 216556 79488562
Dysarthria 56.02 14.69 111 39159 67511 79637607
Joint swelling 55.49 14.69 37 39233 288609 79416509
Progressive multiple sclerosis 54.29 14.69 21 39249 1196 79703922
Nocturia 53.01 14.69 48 39222 13633 79691485
Cystitis 52.95 14.69 94 39176 52638 79652480
Diarrhoea 52.72 14.69 239 39031 880250 78824868
Product use issue 52.24 14.69 19 39251 209803 79495315
Haemoglobin urine present 51.75 14.69 19 39251 936 79704182
Loss of control of legs 50.85 14.69 23 39247 1942 79703176
Urine abnormality 48.94 14.69 37 39233 8182 79696936
Pancytopenia 48.64 14.69 11 39259 165734 79539384
Muscle spasms 48.29 14.69 192 39078 174538 79530580
Nitrite urine present 47.40 14.69 19 39251 1190 79703928
Primary progressive multiple sclerosis 47.21 14.69 11 39259 102 79705016
Paraparesis 46.93 14.69 27 39243 3776 79701342
Blood thyroid stimulating hormone decreased 46.20 14.69 31 39239 5685 79699433
Walking aid user 46.14 14.69 39 39231 10109 79695009
Ankle fracture 46.05 14.69 49 39221 16920 79688198
Lower respiratory tract infection 45.96 14.69 5 39265 129215 79575903
Drug intolerance 45.42 14.69 38 39232 264081 79441037
Bacterial test positive 45.39 14.69 34 39236 7415 79697703
Invasive ductal breast carcinoma 45.34 14.69 31 39239 5861 79699257
Generalised tonic-clonic seizure 45.02 14.69 79 39191 43831 79661287
Treatment failure 44.94 14.69 14 39256 170472 79534646
Hip fracture 44.85 14.69 65 39205 30696 79674422
Tremor 44.70 14.69 184 39086 169899 79535219
Feeling abnormal 44.04 14.69 175 39095 159024 79546094
Magnetic resonance imaging abnormal 43.87 14.69 25 39245 3434 79701684
Temperature intolerance 43.52 14.69 37 39233 9668 79695450
Lymphocyte count abnormal 43.41 14.69 19 39251 1484 79703634
Thrombocytopenia 43.39 14.69 40 39230 265219 79439899
Escherichia test positive 43.12 14.69 24 39246 3151 79701967
Hemiparesis 43.08 14.69 67 39203 33666 79671452
Gastrointestinal haemorrhage 42.95 14.69 10 39260 147709 79557409
Urinary tract infection bacterial 42.79 14.69 31 39239 6425 79698693
Glycosylated haemoglobin increased 42.62 14.69 50 39220 19210 79685908
Musculoskeletal disorder 41.47 14.69 52 39218 21396 79683722
Drug hypersensitivity 41.21 14.69 52 39218 298864 79406254
Urinary tract infection pseudomonal 40.15 14.69 19 39251 1779 79703339
Optic neuritis 40.06 14.69 35 39235 9485 79695633
Product dose omission issue 40.01 14.69 233 39037 247304 79457814
Pericarditis 39.84 14.69 3 39267 104233 79600885
Infusion related reaction 39.73 14.69 33 39237 230204 79474914
Hand deformity 39.69 14.69 3 39267 103916 79601202
Multiple organ dysfunction syndrome 39.52 14.69 6 39264 120240 79584878
Immune reconstitution inflammatory syndrome 39.40 14.69 41 39229 13800 79691318
Blood immunoglobulin M decreased 39.28 14.69 17 39253 1292 79703826
B-lymphocyte count abnormal 38.77 14.69 9 39261 82 79705036
Epilepsy 38.68 14.69 71 39199 40789 79664329
Decreased appetite 38.09 14.69 69 39201 342349 79362769
Abdominal pain 37.80 14.69 85 39185 389484 79315634
Erectile dysfunction 37.43 14.69 41 39229 14623 79690495
Urine odour abnormal 36.82 14.69 28 39242 6245 79698873
General symptom 36.74 14.69 20 39250 2514 79702604
Acute disseminated encephalomyelitis 36.10 14.69 11 39259 302 79704816
Platelet count decreased 36.00 14.69 26 39244 194638 79510480
Extra dose administered 35.54 14.69 31 39239 8384 79696734
Urine ketone body present 35.38 14.69 22 39248 3543 79701575
Hyponatraemia 35.24 14.69 22 39248 177826 79527292
Neutrophil percentage increased 34.50 14.69 24 39246 4665 79700453
Protein urine present 34.40 14.69 33 39237 10079 79695039
Glossodynia 34.31 14.69 5 39265 103332 79601786
Breast cancer 33.63 14.69 60 39210 33721 79671397
Urosepsis 32.97 14.69 52 39218 26443 79678675
Hyperkalaemia 32.75 14.69 8 39262 114390 79590728
Stomatitis 32.19 14.69 16 39254 146741 79558377
Hypoxia 32.05 14.69 6 39264 103237 79601881
Renal failure 32.04 14.69 31 39239 200937 79504181
Pleural effusion 31.61 14.69 16 39254 145246 79559872
Rash 31.60 14.69 162 39108 578196 79126922
Sensory disturbance 31.48 14.69 38 39232 15039 79690079
Exposure during pregnancy 31.13 14.69 6 39264 101126 79603992
Cystitis klebsiella 31.12 14.69 10 39260 328 79704790
Respiratory failure 31.12 14.69 26 39244 180885 79524233
Muscle tightness 31.06 14.69 35 39235 12879 79692239
Cognitive disorder 30.94 14.69 90 39180 69836 79635282
Cardiac failure 30.89 14.69 19 39251 154823 79550295
Pneumonia 30.66 14.69 195 39075 660051 79045067
Weight increased 29.86 14.69 57 39213 277329 79427789
Metabolic acidosis 29.84 14.69 3 39267 82526 79622592
Haematochezia 29.67 14.69 4 39266 87641 79617477
General physical health deterioration 29.25 14.69 57 39213 275181 79429937
Cardiac failure congestive 29.07 14.69 17 39253 142385 79562733
Drug ineffective 28.71 14.69 715 38555 1080198 78624920
Burning sensation 28.42 14.69 78 39192 58554 79646564
Oxygen saturation decreased 28.40 14.69 14 39256 129033 79576085
International normalised ratio increased 28.36 14.69 4 39266 84717 79620401
Vitamin D deficiency 28.21 14.69 35 39235 14244 79690874
Cardiac arrest 28.07 14.69 26 39244 172070 79533048
Arthralgia 28.03 14.69 166 39104 571637 79133481
Rhabdomyolysis 28.02 14.69 8 39262 103123 79601995
Back pain 27.97 14.69 250 39020 303930 79401188
Decreased vibratory sense 27.86 14.69 11 39259 662 79704456
Asthma 27.76 14.69 16 39254 135079 79570039
Coordination abnormal 27.33 14.69 38 39232 17274 79687844
Urinary tract infection enterococcal 26.94 14.69 18 39252 3277 79701841
Sinusitis 26.94 14.69 34 39236 195467 79509651
Vomiting 26.80 14.69 205 39065 665623 79039495
Wheelchair user 26.72 14.69 23 39247 6109 79699009
Contraindicated product administered 26.65 14.69 23 39247 157515 79547603
CD8 lymphocyte percentage decreased 26.47 14.69 4 39266 0 79705118
Vitamin D decreased 26.24 14.69 28 39242 9697 79695421
Limb discomfort 26.09 14.69 53 39217 32797 79672321
Urinary sediment present 26.06 14.69 16 39254 2519 79702599
CD8 lymphocytes increased 26.01 14.69 6 39264 53 79705065
Monocyte percentage increased 25.88 14.69 15 39255 2126 79702992
Hypoglycaemia 25.61 14.69 9 39261 101585 79603533
Arthropathy 25.24 14.69 30 39240 177081 79528037
Neutrophil count increased 25.24 14.69 49 39221 29347 79675771
Decreased interest 25.07 14.69 18 39252 3679 79701439
Swelling 24.68 14.69 43 39227 216668 79488450
Pyrexia 24.56 14.69 215 39055 678494 79026624
Overdose 24.39 14.69 33 39237 184173 79520945
Invasive lobular breast carcinoma 23.87 14.69 10 39260 701 79704417
Therapeutic product effect incomplete 23.57 14.69 21 39249 141624 79563494
Cardio-respiratory arrest 23.54 14.69 12 39258 108498 79596620
Urinary retention 23.26 14.69 71 39199 56559 79648559
Hepatic function abnormal 23.23 14.69 4 39266 73103 79632015
Product use in unapproved indication 23.15 14.69 56 39214 250303 79454815
Human papilloma virus test positive 22.96 14.69 9 39261 531 79704587
Visual impairment 22.88 14.69 98 39172 92033 79613085
Headache 22.84 14.69 450 38820 653322 79051796
Vitamin B12 abnormal 22.81 14.69 6 39264 95 79705023
Prescribed underdose 22.71 14.69 47 39223 29467 79675651
Lymphocyte percentage abnormal 22.70 14.69 5 39265 35 79705083
Urinary tract disorder 22.62 14.69 17 39253 3725 79701393
Red blood cell count abnormal 22.55 14.69 12 39258 1441 79703677
Ascites 22.19 14.69 5 39265 75557 79629561
Speech disorder 22.12 14.69 68 39202 54377 79650741
Fibromyalgia 21.62 14.69 3 39267 64337 79640781
Herpes zoster 21.58 14.69 97 39173 92986 79612132
Urinary tract infection staphylococcal 21.45 14.69 10 39260 905 79704213
Intentional product use issue 21.43 14.69 26 39244 152086 79553032
Lymphocyte count increased 21.40 14.69 20 39250 5912 79699206
Expanded disability status scale score increased 21.20 14.69 9 39261 652 79704466
Intentional overdose 21.13 14.69 13 39257 105947 79599171
Tongue biting 20.83 14.69 13 39257 2108 79703010
Fear of falling 20.77 14.69 9 39261 686 79704432
Maternal exposure during pregnancy 20.69 14.69 22 39248 136516 79568602
Disease progression 20.61 14.69 37 39233 184325 79520793
Mean cell haemoglobin increased 20.58 14.69 17 39253 4268 79700850
Rectal haemorrhage 20.58 14.69 6 39264 76294 79628824
Glucose urine present 20.43 14.69 12 39258 1744 79703374
B-lymphocyte count increased 20.42 14.69 6 39264 145 79704973
Urinary sediment abnormal 20.42 14.69 6 39264 145 79704973
Pulmonary oedema 20.30 14.69 9 39261 88245 79616873
Spinal cord injury cauda equina 20.15 14.69 6 39264 152 79704966
Blood urine present 20.14 14.69 37 39233 21260 79683858
Vitamin D abnormal 20.11 14.69 6 39264 153 79704965
CD4 lymphocyte percentage decreased 20.04 14.69 4 39266 16 79705102
Intervertebral disc protrusion 19.82 14.69 39 39231 23582 79681536
Therapy interrupted 19.68 14.69 46 39224 31295 79673823
Blood thyroid stimulating hormone increased 19.51 14.69 24 39246 9684 79695434
Dysgraphia 19.38 14.69 16 39254 4016 79701102
Vitamin B6 deficiency 19.18 14.69 7 39263 339 79704779
Fatigue 19.00 14.69 595 38675 929132 78775986
Somatosensory evoked potentials abnormal 18.76 14.69 6 39264 194 79704924
Angioedema 18.72 14.69 7 39263 76028 79629090
Bacterial test 18.70 14.69 10 39260 1213 79703905
Anaphylactic reaction 18.55 14.69 9 39261 83734 79621384
Nephrolithiasis 18.43 14.69 63 39207 53228 79651890
Feeling hot 18.42 14.69 68 39202 59666 79645452
Septic shock 18.37 14.69 20 39250 122781 79582337
Hypersensitivity 18.22 14.69 67 39203 262172 79442946
Crystal urine present 18.14 14.69 12 39258 2148 79702970
Rash maculo-papular 17.96 14.69 3 39267 56075 79649043
Citrobacter infection 17.90 14.69 9 39261 961 79704157
Hypokinesia 17.88 14.69 33 39237 19027 79686091
Urobilinogen urine increased 17.69 14.69 8 39262 675 79704443
Skin laceration 17.63 14.69 42 39228 28920 79676198
Proteus test positive 17.48 14.69 7 39263 437 79704681
Wheezing 17.45 14.69 19 39251 116645 79588473
Tibia fracture 17.30 14.69 17 39253 5344 79699774
C-reactive protein increased 17.19 14.69 23 39247 129004 79576114
Neuropathy peripheral 17.05 14.69 27 39243 141278 79563840
Focal dyscognitive seizures 17.01 14.69 14 39256 3498 79701620
Hypokalaemia 16.93 14.69 28 39242 144012 79561106
Dyspnoea exertional 16.93 14.69 11 39259 87062 79618056
Urine uric acid decreased 16.85 14.69 5 39265 125 79704993
Blood pressure fluctuation 16.83 14.69 6 39264 67139 79637979
Red blood cell count increased 16.77 14.69 15 39255 4193 79700925
Hepatic enzyme increased 16.76 14.69 41 39229 182569 79522549
Infection 16.63 14.69 62 39208 241650 79463468
Incontinence 16.53 14.69 27 39243 14137 79690981
Lactic acidosis 16.46 14.69 7 39263 70352 79634766
White matter lesion 16.42 14.69 11 39259 2011 79703107
Insurance issue 16.35 14.69 17 39253 5716 79699402
Haematemesis 16.30 14.69 3 39267 52261 79652857
Blister 16.22 14.69 21 39249 119455 79585663
Wound 16.21 14.69 20 39250 116159 79588959
Pneumonitis 16.02 14.69 5 39265 60855 79644263
Intentional product misuse 15.96 14.69 14 39256 95151 79609967
Hepatotoxicity 15.90 14.69 3 39267 51349 79653769
Frustration tolerance decreased 15.81 14.69 19 39251 7483 79697635
CD4 lymphocytes abnormal 15.80 14.69 4 39266 54 79705064
Haemorrhage 15.78 14.69 13 39257 91105 79614013
Foot fracture 15.75 14.69 34 39236 21947 79683171
Red blood cell count decreased 15.71 14.69 63 39207 57450 79647668
Diplopia 15.70 14.69 44 39226 33422 79671696
Urine cannabinoids increased 15.70 14.69 3 39267 9 79705109
Wrist fracture 15.67 14.69 24 39246 11897 79693221
Lower limb fracture 15.60 14.69 35 39235 23180 79681938
Electrocardiogram QT prolonged 15.52 14.69 13 39257 90373 79614745
Dysdiadochokinesis 15.52 14.69 6 39264 341 79704777
Coma 15.49 14.69 16 39254 100633 79604485
Sensory loss 15.48 14.69 25 39245 12966 79692152
Therapeutic response changed 15.42 14.69 9 39261 1292 79703826
Mean cell haemoglobin decreased 15.19 14.69 17 39253 6207 79698911
Urinary tract obstruction 15.18 14.69 15 39255 4750 79700368
Blood pressure systolic increased 15.14 14.69 7 39263 66979 79638139
Haematocrit decreased 15.05 14.69 65 39205 61247 79643871
Streptococcal urinary tract infection 14.89 14.69 6 39264 381 79704737
Stress 14.88 14.69 78 39192 79534 79625584
Irritable bowel syndrome 14.87 14.69 6 39264 62235 79642883
Chronic kidney disease 14.82 14.69 7 39263 66147 79638971
Renal impairment 14.81 14.69 35 39235 157748 79547370
Plasma cell myeloma 14.71 14.69 4 39266 53255 79651863

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07XX07 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
OTHER NERVOUS SYSTEM DRUGS
Other nervous system drugs
FDA MoA N0000175448 Potassium Channel Antagonists
FDA EPC N0000192795 Potassium Channel Blocker
CHEBI has role CHEBI:33289 avicides
CHEBI has role CHEBI:71031 orphan drugs
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D026902 Potassium Channel Blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Multiple sclerosis indication 24700007 DOID:2377
Seizure disorder contraindication 128613002
Impaired renal function disorder contraindication 197663003




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.58 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-gated potassium channel Ion channel BLOCKER IC50 4.05 CHEMBL CHEMBL
Potassium voltage-gated channel subfamily C member 1 Ion channel BLOCKER IC50 4.50 IUPHAR
Potassium voltage-gated channel subfamily C member 2 Ion channel BLOCKER IC50 4.60 IUPHAR

External reference:

IDSource
4029704 VUID
N0000180628 NUI
D04127 KEGG_DRUG
4025700 VANDF
4025705 VANDF
4029704 VANDF
C0000477 UMLSCUI
CHEBI:34385 CHEBI
4AP PDB_CHEM_ID
CHEMBL284348 ChEMBL_ID
DB06637 DRUGBANK_ID
2416 IUPHAR_LIGAND_ID
1727 PUBCHEM_CID
897018 RXNORM
170373 MMSL
26967 MMSL
NOCODE MMSL
d07546 MMSL
006829 NDDF
413355004 SNOMEDCT_US
80994002 SNOMEDCT_US
D015761 MESH_DESCRIPTOR_UI
7283 INN_ID
BH3B64OKL9 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0479 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 27 sections
dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0509 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL NDA authorized generic 27 sections
dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 0378-4504 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 0591-2533 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 27 sections
AMPYRA HUMAN PRESCRIPTION DRUG LABEL 1 10144-427 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL NDA 27 sections
AMPYRA HUMAN PRESCRIPTION DRUG LABEL 1 10144-427 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL NDA 27 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 16729-292 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 16729-292 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 16729-292 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
DALFAMPRIDINE HUMAN PRESCRIPTION DRUG LABEL 1 42571-275 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
DALFAMPRIDINE HUMAN PRESCRIPTION DRUG LABEL 1 42571-275 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 51407-246 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 51407-246 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 51407-246 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
Dalfampridine Human Prescription Drug Label 1 62756-429 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 27 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 63629-9450 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 63629-9450 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
DALFAMPRIDINE Human Prescription Drug Label 1 65862-863 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Dalfampridine Human Prescription Drug Label 1 67877-444 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Dalfampridine Human Prescription Drug Label 1 67877-444 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Dalfampridine Human Prescription Drug Label 1 67877-444 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections